Introduction to the Groundbreaking Research
For two decades, our genetic map has had gaps and uncharted territories, hindering the precise understanding of genetic variants in complex populations like Mexico’s. This issue is addressed by a new national genomic study, “Clinical Genetic Variation in the Hispanic Populations of the Mexican Biobank,” published in the prestigious journal Nature Medicine.
The Importance of the Study
Led by Mexican researchers from Cinvestav, the National Institute of Public Health (INSP), and the National Institute of Medical Sciences and Nutrition Salvador Zubirán, this study reveals that Mexico’s genetic diversity is not uniform but varies significantly based on region and ancestral roots. This variation directly impacts how Mexicans face diseases and respond to medications.
Addressing Genetic Variability
Dr. Andrés Moreno Estrada, a leading geneticist specializing in Latin American populations, explains that previous medicine precision has relied heavily on studies conducted in European-descendant populations. However, this new study demonstrates that international treatment guidelines are not always applicable in Mexico due to its complex demographic history and rich indigenous heritage.
The study highlights that standard genetic approaches often overlook crucial information in mixed populations like Mexico’s. This “fine print” of the genome determines, for example, an individual’s risk of developing certain diseases or a treatment’s effectiveness.
Case Studies: Fentanyl and Colesterol Treatment
One key finding reveals that medication dosages in Mexican hospitals have been prescribed “blindly” without considering genetic variations. For instance, fentanyl—a crucial anesthetic in surgeries and pain management—depends on a specific genetic variant determining its processing speed. Slow metabolism requires lower doses, while rapid metabolism necessitates higher doses; otherwise, patients face risks from overexposure or underexposure to the drug.
Another example is cholesterol treatment (statins) with the SLCO1B1 gene, which modulates statin effectiveness. Its frequency is 16% in the Mayan region (Chiapas and Yucatan) compared to less than 4% in northern Mexico. This indicates that doctors in the southeast should consider alternative therapeutic options from the outset.
MexVar: Democratizing Genomics
The project also birthed MexVar, a pioneering digital platform in the region based on data from the Mexican Biobank. It aims to be a reference for personalized medicine in the Mexican population by offering a catalog of 42,769 clinically relevant genetic variants. This map allows doctors to check the frequency of risk variants in their specific community.
This level of geographic detail is unprecedented in the continent, surpassing even the resolution of global studies on Hispanic populations conducted by northern powers.
Interinstitutional Effort
This success is the result of a strategic collaboration between Cinvestav, providing analytical power; INSP, responsible for decades of extensive fieldwork; and the National Institute of Medical Sciences and Nutrition Salvador Zubirán, crucial for clinical vision.
With this study, Mexico leads genomic research in Hispanic populations, sending a clear message to the world: precision medicine will only be “precise” if it acknowledges and studies each nation’s diversity.
Key Questions and Answers
- What is the significance of this study? The study reveals that Mexico’s genetic diversity varies significantly based on region and ancestral roots, directly impacting how Mexicans face diseases and respond to medications.
- How does this study differ from previous genomic research? Unlike earlier studies focusing on European-descendant populations, this study addresses the complex demographic history and rich indigenous heritage of Mexico, revealing crucial genetic information previously overlooked.
- What is MexVar and why is it important? MexVar is a digital platform offering a catalog of 42,769 clinically relevant genetic variants in the Mexican population. It allows doctors to check the frequency of risk variants in their specific community, promoting personalized medicine.
- What are some examples of genetic variations impacting medication? One example is fentanyl, an anesthetic whose effectiveness depends on a specific genetic variant determining processing speed. Another example is cholesterol treatment (statins) with the SLCO1B1 gene, which has varying frequencies across Mexico’s regions.
